RVTY Revvity
Intrinsic value$2.73
Price (at call)$143.59
Margin of safety
-98.1%
vs market (rating basis)
-71.7%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | -4.8% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 11.2% |
| Years to target margin | 5 |
| Sales-to-capital | 0.50 |
| Beta | 1.09 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 9.8% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 1.43B |
| PV of terminal value | 1.17B |
| Equity value | 304.44M |
| ÷ shares → per share | $2.73 |
News
neutral +0.10 · 8 articles
- S&P 500 Posts Slight Weekly Decline as Utilities Weigh
- 1 Momentum Stock with Promising Prospects and 2 Facing Headwinds
- Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
- Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks
- 3 Healthcare Stocks That Fall Short
- Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
- Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
- Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 2.77B | -4.8% | 11.2% | 277.89M | 0 | 277.89M | 253.13M |
| 2 | 2.66B | -3.9% | 11.2% | 267.08M | 0 | 267.08M | 221.60M |
| 3 | 2.58B | -3.0% | 11.2% | 259.15M | 0 | 259.15M | 195.86M |
| 4 | 2.53B | -2.0% | 11.2% | 253.86M | 0 | 253.86M | 174.76M |
| 5 | 2.50B | -1.1% | 11.2% | 251.02M | 0 | 251.02M | 157.40M |
| 6 | 2.50B | -0.2% | 11.2% | 250.52M | 0 | 250.52M | 143.09M |
| 7 | 2.52B | 0.7% | 11.2% | 252.35M | 36.39M | 215.96M | 112.36M |
| 8 | 2.56B | 1.7% | 11.2% | 256.52M | 83.16M | 173.36M | 82.15M |
| 9 | 2.62B | 2.6% | 11.2% | 263.13M | 131.81M | 131.31M | 56.68M |
| 10 | 2.72B | 3.5% | 11.2% | 272.34M | 183.70M | 88.63M | 34.85M |
⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.